vbl
therapeutics
announces
appointment
marc
kozin
vice
chairman
board
directors
tel
aviv
israel
globe
newswire
vbl
therapeutics
nasdaq
vblt
today
announced
appointed
marc
kozin
vice
chairman
board
kozin
transition
becoming
chairman
time
bennett
shapiro
current
chairman
board
step
chairman
shapiro
remain
board
directors
honor
serving
chairman
vbl
board
directors
many
years
period
company
significant
accomplishments
transitioned
r
late
clinical
stage
said
bennett
shapiro
happy
pass
role
marc
next
generation
believe
well
qualified
lead
company
fulfill
mission
bring
unique
novel
drug
cancer
dror
harats
chief
executive
officer
vbl
therapeutics
stated
marc
exceptional
track
record
helping
biotech
companies
navigate
success
vbl
continues
evolve
get
ready
provide
patients
need
access
phase
therapy
important
board
members
appropriate
areas
expertise
marc
brings
extensive
professional
strategic
financial
experience
demonstrated
leadership
roles
companies
achieved
success
significant
value
creation
confident
make
important
contributions
marc
kozin
stated
exciting
time
vbl
evidenced
excellent
progress
ongoing
oval
trial
ovarian
cancer
expansion
new
oncology
indications
advancement
pipeline
believe
vbl
deliver
mission
commercialize
treatments
cancer
immune
inflammatory
indications
look
forward
contributing
company
harats
concluded
would
like
thank
shapiro
leadership
pleased
continue
serve
board
marc
kozin
three
decades
industry
expertise
advising
biopharmaceutical
life
sciences
medtech
companies
currently
chairman
strategy
advisory
board
healthcare
royalty
partners
hcr
leading
investment
firm
healthcare
providing
royalty
monetization
senior
debt
previously
kozin
career
strategy
consultant
served
president
consulting
north
american
practice
began
career
helping
establish
boston
office
led
development
industry
leading
life
science
strategic
planning
practice
kozin
served
dozen
boards
variety
roles
committees
currently
lead
independent
director
serves
compensation
committee
ufp
technologies
nasdaq
ufpt
serves
director
chairman
compensation
committee
dicerna
pharmaceuticals
nasdaq
drna
previously
served
board
endocyte
helping
company
negotiate
billion
deal
novartis
also
board
member
dyax
acquired
shire
billion
kozin
served
director
greenlight
fund
focused
improving
lives
inner
city
children
families
since
also
board
governors
new
england
medical
center
board
dukeengage
several
years
received
bs
economics
duke
university
mba
finance
wharton
school
vbl
vascular
biogenics
operating
vbl
therapeutics
clinical
stage
biopharmaceutical
company
focused
discovery
development
commercialization
treatments
areas
unmet
need
cancer
immune
inflammatory
indications
vbl
developed
three
platform
technologies
based
technology
targeting
newly
formed
blood
vessels
focus
cancer
technology
targeting
applications
lecinoxoids
family
indications
vbl
lead
oncology
product
candidate
ofranergene
obadenovec
targeted
agent
developed
treat
wide
range
solid
tumors
conveniently
administered
iv
infusion
every
weeks
observed
cancer
patients
demonstrated
activity
signals
comers
phase
trial
well
three
phase
studies
ofranergene
obadenovec
currently
studied
phase
potential
registration
trial
ovarian
cancer
forward
looking
statements
press
release
contains
statements
statements
statements
historical
fact
statements
often
indicated
terms
anticipate
believe
could
estimate
expect
goal
intend
look
forward
may
plan
potential
predict
project
would
similar
expressions
statements
include
limited
statements
regarding
programs
including
including
clinical
development
timing
clinical
trials
expected
announcement
data
therapeutic
potential
clinical
results
financial
position
cash
runway
statements
promises
guarantees
involve
substantial
risks
uncertainties
among
factors
could
cause
actual
results
differ
materially
described
projected
herein
include
uncertainties
associated
generally
research
development
clinical
trials
related
regulatory
reviews
approvals
risk
historical
clinical
trial
results
may
predictive
future
trial
results
impact
pandemic
business
operations
clinical
trials
supply
chain
strategy
goals
anticipated
timelines
clinical
results
financial
resources
last
long
anticipated
may
realize
expected
benefits
intellectual
property
protection
list
description
risks
uncertainties
risks
found
regulatory
filings
securities
exchange
commission
including
annual
report
form
year
ended
december
subsequent
filings
sec
existing
prospective
investors
cautioned
place
undue
reliance
statements
speak
date
hereof
vbl
therapeutics
undertakes
obligation
update
revise
information
contained
press
release
whether
result
new
information
future
events
circumstances
otherwise
investor
contact
michael
rice
lifesci
advisors
mrice
